Ferlitsch, Arnulf, Puspok, Andreas, Bota, Simona, Wewalka, Friedrich, Schoefl, Rainer, Brownstone, Eva, Madl, Christian, Lenzen, Henrike, Lankisch, Tim O, Dolak, Werner, Trauner, Michael H and Ferlitsch, Monika
(2016)
Efficacy and safety of bovine activated factors IIa/VIIa/IXa/Xa in patients with active gastrointestinal bleeding: a proof of concept study.
Endoscopy, 48 (4).
pp. 380-4.
ISSN 1438-8812
Full text not available from this repository.
Abstract
BACKGROUND AND STUDY AIMS
Endoscopic treatment of active gastrointestinal bleeding often remains difficult, and considerable technical expertise is required. Our aim was to assess the efficacy and safety of endoscopic hemostasis with a liquid combination of bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal).
METHODS
Patients with active gastrointestinal bleeding were prospectively included. In group A, 5 mL of bovine activated factors IIa/VIIa/IXa/Xa was topically applied via catheters to the bleeding site as initial hemostasis; group B received a similar application but as rescue therapy after failure of conventional endoscopic hemostasis.
RESULTS
In group A, bleeding was stopped by the agent in 15 /22 patients (68 %) and by conventional endoscopic hemostasis in 5 of the other 7, with coiling and surgery required for definitive hemostasis in 2. In group B, the addition of the agent definitively stopped bleeding in 13 /15 patients (87 %), with hemostasis in the remaining 2 achieved with fibrin glue. Rebleeding was observed in 1 patient.
CONCLUSIONS
Our proof of concept study suggests that the use of bovine activated factors IIa/VIIa/IXa/Xa might be a safe and effective addition to current endoscopic hemostatic strategies, but further studies are necessary.ClinicalTrials.gov identifier: NCT02349490.
Actions (login required)
- View Item